An animal study of printed nerve guides, an essay asking when you're healthy enough, and a cereal industry chasing protein as Americans buy less.
Picked from 48 new articles across 12 sources · arrow keys for other days
Today in 30 seconds
30s left
3D-printed tubes carrying living Schwann cells helped animals regrow damaged peripheral nerves. They could one day replace nerve grafts taken from the patient, but this is animal work only. story 1 ↓
An emergency nurse practitioner argues that medicine defines disease but never 'healthy enough,' and should judge health by what your body lets you do. story 2 ↓
Americans bought 13% less cereal than in 2021, and dollar sales are falling too. Makers are responding with protein and fiber as GLP-1 drugs reshape appetites. story 3 ↓
A new federal rule will make pharmacy benefit managers disclose fees and payments they now keep private, giving a clearer view of how drug prices are set.
Researchers printed fine strands of gel carrying Schwann cells, the cells that support nerves, and built them into implantable tubes. In animals, these tubes helped nerves regrow and recover function. The summary gives no effect sizes.
Why it matters · Large nerve gaps are usually bridged with nerve tissue taken from elsewhere in the patient's body. An off-the-shelf artificial guide would avoid a second surgery, but this work is still at the animal stage.
Know this first
Context from the editor, not the article · 33 sec
1 · Repairing nerve gaps today
Cut peripheral nerves can regrow, but this gets harder as the gap widens. Surgeons often bridge a gap with an autograft: a less important nerve taken from elsewhere in the patient. That means a second wound, numbness where it was taken, and a limited supply.
2 · Nerve guidance conduits
These are artificial tubes stitched between the two cut ends of a nerve to guide regrowing axons, the long fibres nerve cells send out. Hollow tubes work for short gaps. Adding internal structure and supportive cells aims to make them work over longer gaps.
3 · Schwann cells
2/3Sensible Medicine· Kirsten Balin· Oct 31
A clinician argues medicine should measure health by what your body lets you do
Kirsten Balin, a family nurse practitioner in rural Oregon, argues that medicine confuses lab numbers with health. She proposes counting whether your body still lets you live your life, without giving up screening.
Why it matters · If you track biomarkers or chase lower targets, this essay asks a useful question: what is the extra risk reduction meant to protect?
Know this first
Context from the editor, not the article · 29 sec
1 · Why prevention needs numbers
Many serious conditions, such as high blood pressure, diabetes and early cancers, cause no symptoms for years. Preventive medicine uses measurements and screening to catch them before harm occurs, so feeling well cannot rule them out.
2 · Overdiagnosis and incidental findings
Doing more tests turns up more abnormalities, such as thyroid nodules, bulging discs or slightly abnormal lab values. Many of these would never cause harm. Treating or chasing them can bring cost, worry and side effects without any benefit.
3 · Targets keep moving lower
Guidelines for LDL cholesterol and blood pressure have tended to push targets down over time. Trials often show small further reductions in risk at lower levels, so there is usually some risk left to treat.
3/3Food Politics (Marion Nestle)· Marion· Oct 28
US breakfast cereal sales are falling, and makers are pitching protein and fiber
Marion Nestle rounds up reports on the shrinking US cereal business. Volume is down 13% since 2021. Makers like WK Kellogg are adding protein and fiber, cutting sugar and selling into schools.
Why it matters · Health worries, appetite-suppressing GLP-1 drugs and pressure to cut processed food are changing what a major packaged food is made of and how it's marketed to children.
Know this first
Context from the editor, not the article · 27 sec
1 · Who WK Kellogg is
WK Kellogg Co is the North American cereal business (Froot Loops, Frosted Flakes) that the Kellogg Company split off in 2023. The snacks side became a separate company, Kellanova. Battle Creek, Michigan, is cereal's historic home.
2 · GLP-1 drugs and appetite
GLP-1 drugs such as semaglutide (Ozempic, Wegovy) copy a gut hormone that slows digestion and reduces appetite. Food companies watch them closely because people taking them tend to eat less, especially less sweet and processed food.
3 · Make America Healthy Again
"Make America Healthy Again" (MAHA) is the movement linked to US Health Secretary Robert F. Kennedy Jr. It pushes against ultra-processed foods, synthetic dyes and added sugar, especially in food for children.
These cells wrap peripheral nerve fibres in myelin, a fatty insulating layer. After an injury they also line up into tracks that lead regrowing axons across the gap. That makes them an obvious ingredient for an artificial guide.
Image: Fight Aging!
A research team has printed fine strands of gel carrying living 1, the cells that support and insulate peripheral nerves. They built the strands into an implantable tube to guide cut nerves as they regrow, and in animal tests it helped nerves regrow and recover function. Fight Aging! covered the paper (doi:10.1088/2631-7990/aea8a3) but quoted only its abstract, so most numbers are missing.
The problem
Cut peripheral nerves can regrow, but wide gaps often fail to heal. Surgeons usually bridge them with an 2, a piece of nerve taken from elsewhere in the patient. That means a second wound and a limited supply. The goal is a cheap artificial guide that works as well.
The printing fix
The team started from cell-laden electro-direct writing (CEDW). An electric field draws a thin jet of 3, a printable gel containing living cells, into fine filaments. The difficulty is that an ink runny enough to print well tends to make weak strands, and changes that strengthen the strands can harm the cells.
The new version, temperature-regulated CEDW (TCEDW), precisely controls the ink cylinder's temperature to change how the ink flows at each stage of printing. The authors say this separates printability from cell survival. They report a resolution of 36.05 micrometres, under half the width of a hair. The ink combined alginate (a seaweed gel), gelatin methacryloyl or 4 (a gelatin cells can grip) and polyethylene oxide or PEO (a polymer that helps form the jet), with Schwann cells mixed in.
What it did
In dishes, the printed strands were grown alongside 5 cells, a rat cell line that can be coaxed into neuron-like behaviour. Their 6, the sprouts that become nerve fibres, lined up along the strands and matured more. The abstract calls this significant without giving sizes. Gene analysis showed axon guidance genes and the 7 signalling pathway switched on, and cell-division programs switched off. The cells were committing to become neurons.
The team then combined TCEDW with two other electric-field methods, melt electrowriting and electrospinning, to make a three-layer nerve guidance conduit (NGC), a tube sutured between the cut nerve ends. In animals, it promoted fibre regrowth, Schwann cell migration, 8 (rebuilding the insulating sheath around nerve fibres) and functional recovery.
Caveats
The available text gives no species, gap length, follow-up time or effect sizes. Above all, it doesn't say whether the conduit matched an autograft, which is the real benchmark. Implants containing living cells also face harder manufacturing and regulatory paths than simple tubes. This is an early-stage engineering result, not a near-term treatment.
A team has reported a way to print strands of gel that carry living 1, the cells that support and insulate peripheral nerves. They built these strands into an implantable tube that guides a cut nerve as it regrows. In animal experiments the tube promoted nerve regrowth and some return of function. Fight Aging! covered the paper (doi:10.1088/2631-7990/aea8a3). The coverage reproduces only the abstract, so the methods can be described but most of the numbers can't.
The problem
Peripheral nerves can regrow across a cut. The wider the gap, though, the less likely the regrowing fibres are to find their target. The standard bridge is an 2, a piece of nerve taken from elsewhere in the patient. Reason, the Fight Aging! writer, calls such grafts "far from optimal." They mean a second surgery and lost sensation where the donor nerve came from. Researchers therefore want artificial guides that are cheap and restore function reliably.
Why printing cells is hard
The researchers worked with a printing method called cell-laden electro-direct writing (CEDW). An electric field pulls a very thin jet of 3, a printable gel mixed with living cells, out of a nozzle and lays it down as a fine filament. The authors say CEDW struggles to balance three things:
Printability: the ink must flow smoothly through a thin jet.
Mechanical integrity: the printed strand must hold its shape afterwards.
Biocompatibility: the cells must survive the process.
Changing the ink to improve one of these tends to hurt another. The authors say this is why CEDW has seen little use in nerve tissue engineering.
What they changed
Their version is temperature-regulated CEDW (TCEDW). The ink cylinder is held at precisely controlled temperatures so that the ink's flow behaviour (its rheology) suits each stage of printing. Gelatin-based gels thicken as they cool and thin as they warm, which is how temperature can tune them. The abstract doesn't give the temperatures used or describe the stages. The authors say this "decouples" printability from biocompatibility: the ink can be made easy to print at one moment without compromising cell survival or the strand's final strength. They report a print resolution of 36.05 micrometres, roughly a third to half the width of a human hair.
The bioink combined three materials, each with a conventional role in this field:
alginate, a seaweed-derived gel that sets quickly;
gelatin methacryloyl (4), a modified gelatin that cells can attach to and that can be hardened with light;
polyethylene oxide (PEO), a polymer often added to help a jet form.
Schwann cells were mixed into the ink before printing. The abstract reports better shape fidelity alongside preserved cell viability but gives no survival percentage.
What the lab tests showed
In dishes, the team grew the printed Schwann-cell filaments together with 5 cells. PC12 is a standard rat cell line that can be induced to behave like neurons and sprout 6, the projections that become axons and dendrites. On the printed filaments, neurites lined up along the strands and matured more than in comparison conditions. The abstract calls the difference significant but gives no magnitude. The authors attribute this to two cues working together: the physical grooves of the strands and the chemical signals from the Schwann cells.
Gene expression analysis suggested a mechanism. The scaffolds switched on axon guidance genes and the 7 signalling pathway, a cell-signalling route involved in growth-cone steering and neuronal differentiation. They switched off proliferation programs. Put simply, the PC12 cells divided less and became more neuron-like.
Building the conduit
For implantation, the team combined three electric-field techniques into one three-layer nerve guidance conduit (NGC), a tube sutured between the two nerve ends:
Melt electrowriting draws molten polymer into precise fibres, typically used for a strong outer frame.
Electrospinning produces dense mats of very fine fibres, often used as a barrier wall.
TCEDW lays down the cell-carrying inner filaments.
The abstract doesn't say which layer sits where or what each one does. That layout is the usual logic of such designs, not something stated in the source.
Results in animals and what's missing
According to the abstract, the composite conduit promoted nerve fibre regrowth, Schwann cell migration, 8 (rebuilding the insulating sheath around axons) and functional recovery. The available text leaves out what a reader needs to judge this:
the animal species and the length of the gap repaired;
the comparison groups, especially whether the conduit was tested against an autograft, the bar any clinical alternative must clear;
effect sizes for regrowth or function, and how long the animals were followed.
Without these, the honest summary is that the method works as a lab technique and shows positive animal results of unknown size. Cell-laden implants also face hurdles in reaching the clinic that cell-free tubes avoid: where the cells come from (donor or the patient's own), manufacturing consistency, sterility and regulatory approval. The paper is one step in a long-running effort to replace nerve grafts. It isn't evidence that patients will benefit soon.
Remember
Controlling ink temperature lets printers make cell-carrying strands about 36 micrometres wide that keep their shape and keep cells alive.
The printed strands provide physical grooves and Schwann cell signals, and these together lined up and matured neuron-like cells.
No published comparison with nerve autografts appears in the text, and that comparison decides whether the conduit could reach clinics.
Kirsten Balin is a 1 (FNP). She works in an emergency department and runs a practice in rural Oregon. In an essay for 2, a newsletter that covers medicine without industry funding, she asks what "healthy" actually means. There is no data here. It is a clinician's argument, and it should be read that way.
Feeling fine isn't enough
Balin accepts the case for 3. A blood pressure of 190/110 is dangerous even if the patient feels great. So is an 4 (a blood test of average blood sugar over about three months) of 11. An early cancer may cause no symptoms. Waiting for disease to announce itself would be bad medicine.
"Nothing wrong" isn't the answer either
She contrasts two kinds of patients. The first are people in their seventies who take several medications and have sore arthritic knees. They still hunt, garden and help with grandchildren, and they call themselves healthy. The second are younger patients with normal labs and scans who are sure the right test simply hasn't been ordered yet.
Her point is that with enough tests, almost anyone shows something: an odd lab value, a thyroid nodule, a bulging disc, a few extra heartbeats. Many of these findings are harmless. Looking makes sense when it matters, she writes, but not every finding is "a verdict."
The number should serve the patient
No patient, Balin notes, sets "an 5 of 68" as a life goal. LDL is the "bad" cholesterol that drugs like statins lower. People want to keep traveling, farming, and getting down on the floor with grandchildren and back up again. Numbers matter because improving them may protect those things.
But there is always a lower target. An LDL of 130 can go to 100, then 70, then 55. Blood pressure can nearly always come down a bit more. Medicine, she says, has "plenty of thresholds for when something becomes a problem" and "remarkably few for when someone is healthy enough." She suggests annual visits should ask "What are we trying to preserve?" as well as "What risks can we reduce?"
Caveats
She concedes that function alone can't define health, because silent disease exists. The essay also doesn't say how to decide when risk is low enough. Trials of many risk factors show benefits continuing at lower levels, though each step down gives less. Choosing where to stop is a trade-off between side effects, pill burden and what the patient values. Balin names the problem without settling it.
An essay, not a trial
This piece ran on 1, a newsletter edited by internist Adam Cifu that covers medicine without industry funding. It is an opinion essay. It reports no study, no effect sizes and no data. The author is Kirsten Balin, a 2 (FNP). She works in an emergency department and owns a practice in rural Oregon. Her question sounds simple: what counts as being healthy? Her answer is that medicine has grown so good at measuring health that it has started to treat the measurements as the thing itself. She thinks a person's ability to use their body to live their life deserves more weight than it gets now.
Why "feeling fine" can't be the definition
Balin starts by ruling out the easy answer. Feeling good is not enough. A blood pressure of 190/110 is dangerous however well the patient feels. So is an 3 (a blood test showing average blood sugar over about three months) of 11, when the diabetes threshold is 6.5. An early cancer may cause no symptoms at all. The whole case for 4 is "finding trouble before it feels like trouble," and she accepts it.
So she is not arguing against screening or risk-factor treatment. She is asking whether the opposite definition, a body with nothing wrong with it, works any better.
Why "nothing wrong" doesn't work either
She sets two kinds of patients side by side. The first are people in their seventies who take several medications and have arthritis in "several inconvenient places." They know which chair is easiest to get out of and keep ibuprofen in the truck. They still hunt, travel, garden and help with grandchildren, and they call themselves healthy. The second are younger patients whose labs, imaging and vital signs are all normal, but who are increasingly convinced that the right test hasn't been ordered yet.
Which group is healthier? Balin says her measurements can't answer that. Her broader point concerns test volume: "Give me enough blood tests and imaging procedures, and I can find something wrong with you." She lists the kinds of things more testing turns up, including an out-of-range lab value, a thyroid nodule, a bulging disc and a few premature heartbeats. Clinicians call these 5, and many never cause harm. Her line is that looking when it matters is fine, but not every finding is "a verdict." Symptoms work the same way. Bodies ache and tire, and a 40-year-old body doesn't feel like a 20-year-old one. She asks when we decided that meant being unhealthy.
She uses herself as an example. Some nights she wakes at 3 a.m. Some weeks running feels easy and some weeks it doesn't. She knows she could track a sleep score or 6 (the maximum rate at which the body can use oxygen, a common fitness measure) and improve it. Mostly she chooses not to. She can work twelve-hour shifts, hike, run, travel and paint her bedroom. In her words, a healthy body "has to let you live your life."
The number should serve the patient
The core of the argument concerns treatment targets. No patient, she writes, says their life's ambition is "an 7 of 68." LDL is the "bad" cholesterol that statins and similar drugs lower. Patients want to keep hunting, to have the stamina to travel, and to get down on the floor with grandchildren and get back up. Numbers matter because lowering them may prevent the events that would take those things away. The number serves the patient, not the other way round.
The trouble is that there is always a better number. Her example is an LDL that goes from 130 to 100, then to 70, then to 55. Blood pressure can nearly always go a little lower, and weight can always drop a few more pounds. In her words, medicine has "plenty of thresholds for when something becomes a problem" but "remarkably few for when someone is healthy enough."
She suggests that an annual visit should ask "What are we trying to preserve?" as well as "What risks can we reduce?" She says she can't define health cleanly and distrusts anyone who claims they can. Any definition, she argues, has to allow for imperfection, or no one will meet it for long.
How to weigh it
This is a clinician's reflection, so judge it as an argument. It is not evidence. Some points are fair to add:
She concedes the main counterargument herself. Function alone fails because disease "does not always have the courtesy to make itself known." Her proposal is to add weight to function, not to swap it in for risk numbers.
"Healthy enough" thresholds are hard to set. For many risk factors, trials show benefit continuing at lower levels, though each step down gives a smaller absolute gain. Deciding where to stop is a judgment about trade-offs: side effects, pill burden, cost and what the patient values. Balin raises that judgment but doesn't say how to make it.
The two patient types are illustrations, not data. The essay doesn't say how common either type is, or whether worry-driven testing leads to measurable harm in her practice.
Her framing fits two existing ideas in medicine. One is 8, where patient and clinician choose treatment together based on the patient's goals. The other is the growing focus in geriatric care on function and "what matters" to the patient. The essay doesn't cite either.
Remember
Medicine has many thresholds for disease but almost none for when someone is "healthy enough."
With enough testing, almost anyone shows an abnormality, and many of these findings are harmless.
The essay supports screening but asks clinicians to weigh it against what patients want to keep doing.
Ted Kyle's AI illustration of what Nestle calls her favorite example of absurd cereal marketing.
Marion Nestle, a nutrition professor and food-industry critic, has rounded up recent reporting on the US breakfast cereal business on her Food Politics blog. She co-wrote a new book on the subject, Sugar Coated, with Lisa Sutherland, a former vice president for nutrition at the Kellogg Company. The post links to other coverage and reports no new research.
A shrinking business
The New York Times puts US cereal sales at nearly $13 billion. According to 1, a retail-tracking firm, shoppers bought 13% less cereal last year than in 2021. Sales rose briefly during the pandemic and then fell off. Dollar sales are falling too, even though prices have gone up. Battle Creek, Michigan, once home to more than 100 cereal companies, has lost thousands of cereal jobs.
Why people are buying less
The reporting lists several pressures, though none is measured on its own:
Shoppers see cereal as highly processed, sugary and low in nutrients. Nestle and Sutherland call it "vitamin-supplemented cookies."
Busy people eat bars on the go or skip breakfast.
The "2" movement, linked to Health Secretary Robert F. Kennedy Jr., is pushing against processed food.
Appetite-suppressing 3 drugs such as 4 are spreading.
Higher prices mean cereal no longer stretches a grocery budget the way it did.
The industry's answer
5, the maker of Froot Loops and Frosted Flakes, is changing its well-known brands. It is adding protein and fiber, cutting sugar, and launching products for schools meant to win over "the next generation of eaters." Ted Kyle of the obesity-policy blog 6 asks whether protein and fiber can save the category.
Sutherland is skeptical that anything is really changing. "The more things change, the more things stay the same in the cereal industry," she told the Times. "They just keep cycling back to their roots." Cereal began as a health food, and a protein-and-fiber pitch brings back that old message.
How to read it
This is news about markets and marketing, not about health. No study here shows the reformulated cereals do anything for health. The articles don't give the new sugar, protein or fiber amounts, so you can't tell real reformulation from relabeling. The school products also go undescribed. The post doesn't say how much of the decline GLP-1 drugs explain, either. Nestle points readers to her book for the history and the reasons behind it.
Marion Nestle, a nutrition professor and long-time critic of the food industry, has written a short post on her Food Politics blog collecting recent reporting on the US breakfast cereal business. She has a stake in the subject: she co-wrote a new book about it, Sugar Coated: Unboxing the Hidden Forces Shaping America's Favorite Breakfast Food, with Lisa Sutherland. Sutherland was once vice president for nutrition at the Kellogg Company and is now interim president of Jacksonville University. The post is mostly links and quotes. It reports no new research. What it gives is a picture of an industry in decline and how that industry is trying to recover.
The numbers
The New York Times piece by Kim Severson, which Nestle cites, puts the US cereal business at nearly $13 billion. According to 1, a firm that tracks retail sales, shoppers bought 13% less cereal last year than in 2021. Sales rose briefly during the pandemic, when more people ate breakfast at home. Since then the volume has fallen away. Dollar sales are also declining even though prices have gone up. That matters because companies often cover falling volume by charging more, and here that hasn't worked.
Food Dive's Christopher Doering gives the long view from Battle Creek, Michigan. Early in the 20th century the town had more than 100 cereal companies, and thousands of cereal jobs there have since disappeared.
Why people are buying less
The reporting offers several overlapping reasons. None is measured separately in the article, so treat this as a list of likely causes, not a ranking:
Reputation. Shoppers increasingly see cereal as highly processed, high in sugar and short on nutrients. Nestle and Sutherland's phrase for it is "vitamin-supplemented cookies": sugary grain products made to look healthy by adding vitamins and minerals.
Changing habits. Busy people grab bars and other portable foods, or skip breakfast, instead of eating a bowl at home.
Politics. The "2" movement is pushing for less-processed food.
3 drugs. Appetite-suppressing medicines such as 4 are spreading. The articles name them as a pressure on sales but give no figures for how much.
Price. Cereal used to be a cheap way to stretch a grocery budget, and higher prices have weakened that appeal.
The industry's response
According to the coverage Nestle links, 5, the maker of Froot Loops and Frosted Flakes, is changing well-known brands. It is adding protein and fiber and cutting sugar. It is also launching products aimed at schools, a strategy the company describes as winning over "the next generation of eaters." Ted Kyle, who writes the obesity-policy blog 6, puts the question as whether protein and fiber can save a struggling category. Severson describes the same move more broadly: the industry is trying to cash in on Americans' current interest in wellness.
Sutherland doubts this is anything new. "The more things change, the more things stay the same in the cereal industry," she told the Times. "They just keep cycling back to their roots." Cereal started out as health food (the Kellogg brothers sold it in a sanitarium context) before advertising and sugar took over. A protein-and-fiber pitch is a return to a health message the industry has used before.
What to make of it
For readers who follow the evidence, a few points matter.
First, this is market and marketing news, not nutrition science. The post cites no trial or cohort study showing that the reformulated cereals improve health. The articles don't give the specific sugar, protein or fiber amounts for the new versions, so you can't judge how big the changes are. Cutting a few grams of sugar per serving and rebranding the box are very different things, and the article doesn't let you tell which one is happening.
Second, the school strategy deserves attention. School meals follow federal nutrition standards, and products designed for them are a way to build brand loyalty early. The article says the products exist but describes neither their formulation nor how they meet those standards.
Third, adding protein and fiber can make a product sound healthier without changing what it fundamentally is: a refined, processed grain product. Nestle has long argued that "better-for-you" versions of processed foods are mostly marketing. The post points to her book for that argument. She also says Kyle's AI-generated illustration shows her "current favorite example of hilarious marketing," but the text never says which product it shows.
What's left open
The post doesn't say how much of the decline each cause explains, especially the GLP-1 share, which would be the most interesting number to have. It doesn't say whether reformulated cereals are selling better, or what's actually in the school products. For those answers, Nestle points readers to Sugar Coated, which she says explains the history and the reasons behind it.
Remember
Higher cereal prices haven't kept dollar sales from falling, so price increases aren't covering the drop in volume.
Adding protein and fiber can improve a cereal's image without showing any health benefit, and no figures or studies were offered.
Products designed for school meals are how cereal makers hope to build loyalty in children.
